Stocktoria
GSK plc GSK.L
GB · London Stock Exchange · XLON · stock · Healthcare · website
GSK plc financials (annual)
Bars are annual figures from 2022 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | £32.7B | £31.4B | £30.3B | £29.3B |
| Gross profit | £23.6B | £22.3B | £21.8B | £19.8B |
| R&D expense | £7.5B | £6.4B | £6.2B | £5.5B |
| SG&A expense | £9.1B | £11.0B | £9.4B | £8.4B |
| Operating income | £8.3B | £5.5B | £7.3B | £6.7B |
| Interest expense | £687.0M | £640.0M | £725.0M | £826.0M |
| Income tax | £1.1B | £526.0M | £756.0M | £707.0M |
| Net income | £5.7B | £2.6B | £4.9B | £15.0B |
| EPS (diluted) | £1.39 | £0.62 | £1.20 | £3.66 |
| Operating cash flow | £7.7B | £6.6B | £6.8B | £7.4B |
| Free cash flow | £4.8B | £3.6B | £4.4B | £5.1B |
| Cash & equivalents | £3.1B | £3.7B | £2.7B | £3.5B |
| Inventory | £5.9B | £5.7B | £5.5B | £5.1B |
| Goodwill | £7.0B | £7.0B | £6.8B | £7.0B |
| Total assets | £61.1B | £59.5B | £59.0B | £60.1B |
| Total debt | £17.7B | £17.0B | £18.0B | £21.0B |
| Total liabilities | £45.2B | £46.4B | £46.2B | £50.0B |
| Shareholders' equity | £16.4B | £13.7B | £13.3B | £10.6B |
| Share buybacks | £1.4B | £0 | £0 | — |
Growth · year-over-year · Revenue CAGR 3.7%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue growth | +4.1% | +3.5% | +3.4% | — |
| Net income growth | +122.0% | -47.7% | -67.1% | — |
| EPS growth | +123.2% | -48.1% | -67.3% | — |
| Free cash flow growth | +33.1% | -19.3% | -14.0% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · GB · as of 2025-12-31. Figures in GBP. Facts plus Stocktoria's own computed scores — not investment advice.